dimercaprol

dimercaprol
Drug name	Dimercaprol
Tradename	BAL
Routes of administration	Intramuscular
Class	Chelating agent

dimercaprol is an organosulfur chelating agent used in the management of heavy metal poisoning. It is employed as an antidote in cases involving arsenic, gold, mercury, and lead, and has been used historically in military and industrial poisoning incidents. Developed in the mid-20th century, dimercaprol remains listed on several essential medicines lists and appears in treatment protocols of emergency medicine, toxicology, and occupational health.

Medical uses

Dimercaprol is indicated for acute poisoning with inorganic arsenic, organic mercury, inorganic mercury, gold salts, and lead compounds, and is used in combination with other agents in complex cases involving World Health Organization, Centers for Disease Control and Prevention, United States Public Health Service, National Institutes of Health, and regional poison control centers. In arsenic poisoning related to industrial accidents or alleged exposure such as incidents investigated by Occupational Safety and Health Administration or Environmental Protection Agency, dimercaprol has been administered alongside supportive care protocols endorsed by American College of Medical Toxicology and European Association of Poisons Centres and Clinical Toxicologists. It has also been used during outbreaks or contamination events overseen by agencies such as United Nations Environment Programme and Food and Agriculture Organization. In lead encephalopathy and severe lead poisoning, dimercaprol may be combined with chelators recommended by guidelines from American Academy of Pediatrics and World Federation of Societies of Anaesthesiologists in pediatric critical care. For gold or mercury poisoning from medical therapies or artisanal mining exposures investigated by Médecins Sans Frontières or Centers for Disease Control and Prevention, dimercaprol has been part of emergency regimens described in case series published with collaboration from Johns Hopkins University and Harvard Medical School clinicians.

Mechanism of action

Dimercaprol functions by coordinating heavy metal ions via its two sulfhydryl groups, forming stable, water-soluble complexes that reduce tissue binding and enhance renal excretion. This chelation mechanism is discussed in pharmacology texts and reviews from institutions such as University of Oxford, Massachusetts Institute of Technology, Stanford University School of Medicine, Karolinska Institutet, and University of Cambridge. The agent’s high affinity for soft metal cations is explained in organometallic chemistry literature and toxicology monographs associated with Royal Society of Chemistry, American Chemical Society, National Academy of Sciences, and Royal Institution. In complex poisoning scenarios, dimercaprol’s interactions with other chelators such as succimer and EDTA are considered in protocols developed by World Health Organization, American Heart Association, and European Medicines Agency.

Pharmacokinetics

After intramuscular administration, dimercaprol is absorbed and distributes to tissues with kinetics characterized in studies from Mayo Clinic, Cleveland Clinic, University College London, Karolinska Universitetssjukhuset, and McGill University Health Centre. It undergoes hepatic metabolism and the metal–dimercaprol complexes are primarily excreted in urine, as described in pharmacokinetic reports from Food and Drug Administration, European Medicines Agency, National Institute for Occupational Safety and Health, and clinical pharmacology reviews published by The Lancet and New England Journal of Medicine. Dose adjustment considerations for renal or hepatic impairment appear in formularies by British National Formulary, American Hospital Formulary Service, and institutional guidelines at Massachusetts General Hospital and Toronto General Hospital.

Adverse effects and toxicity

Adverse effects include pain at the injection site, hypertension, tachycardia, nausea, headache, and fever; severe effects such as nephrotoxicity or hematologic reactions have been reported in case series from Mount Sinai Hospital, Royal Free Hospital, Beth Israel Deaconess Medical Center, University of Sydney and Charité – Universitätsmedizin Berlin. Because of its narrow therapeutic index, monitoring is recommended by World Health Organization, Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control and specialty societies like Society of Critical Care Medicine and American College of Medical Toxicology. Interactions with other metals and chelating agents, and rare hypersensitivity reactions documented in reports from St Bartholomew's Hospital, Guy's and St Thomas' NHS Foundation Trust, Vanderbilt University Medical Center, and University of California, San Francisco inform risk–benefit assessments.

Chemistry and formulation

Chemically, dimercaprol is 2,3-dimercapto-1-propanol, an organosulfur compound with two vicinal thiol groups; its structure and reactivity are described in publications from Royal Society of Chemistry, American Chemical Society, Chemical Society of Japan, and academic departments at University of California, Berkeley, ETH Zurich, University of Tokyo and Sorbonne University. The drug is formulated in an oil-based solution for intramuscular injection to reduce volatility and enhance stability, with production and quality standards overseen by World Health Organization, United States Pharmacopeia, and European Pharmacopoeia. Manufacturing and supply considerations have involved collaborations with pharmaceutical manufacturers regulated by Food and Drug Administration and European Medicines Agency.

History and development

Dimercaprol was developed in the 1940s as an antidote to arsenical warfare agents and industrial arsenic exposures, with early work conducted under wartime research programs associated with United States Army, Ministry of Supply (United Kingdom), National Research Council (Canada), and scientists at University of Chicago and Johns Hopkins University. Clinical adoption expanded in the 1950s and 1960s following reports in journals connected to Royal Society, The Lancet, and New England Journal of Medicine, and officials at World Health Organization and national public health agencies incorporated dimercaprol into emergency response arsenic protocols. Subsequent development of oral chelators such as succimer influenced practice patterns described by American Academy of Pediatrics and Centers for Disease Control and Prevention, but dimercaprol retains a role in modern toxicology, emergency medicine, military medicine, and occupational health responses coordinated by World Health Organization, United Nations, and national health services.

Category:Antidotes Category:Organosulfur compounds